Cancer detection · detecting colon cancer in patients with inflammatory bowel disease
It is very uncertain whether surveillance changes cancer detection compared with non surveillance (very low certainty).
1 finding from 1 review
Death from colorectal cancer · detecting colon cancer in patients with inflammatory bowel disease
It is very uncertain whether surveillance changes death from colorectal cancer compared with non surveillance (very low certainty).
1 finding from 1 review
Cancer stage‐ Duke A or B · detecting colon cancer in patients with inflammatory bowel disease
It is very uncertain whether surveillance changes cancer stage‐ Duke A or B compared with non surveillance (very low certainty).
1 finding from 1 review
Cancer stage‐ Duke C or D · detecting colon cancer in patients with inflammatory bowel disease
It is very uncertain whether surveillance changes cancer stage‐ Duke C or D compared with non surveillance (very low certainty).
1 finding from 1 review
Recurrent pyelonephritis · pregnant women with a history of one or more UTI before or during pregnancy
It is very uncertain whether nitrofurantoin and close surveillance changes recurrent pyelonephritis compared with close surveillance alone (very low certainty).
1 finding from 1 review
Recurrent UTI (cystitis) · pregnant women with a history of one or more UTI before or during pregnancy
It is very uncertain whether nitrofurantoin and close surveillance changes recurrent UTI (cystitis) compared with close surveillance alone (very low certainty).
1 finding from 1 review
Preterm birth · pregnant women with a history of one or more UTI before or during pregnancy
It is very uncertain whether nitrofurantoin and close surveillance changes preterm birth (< 37 weeks) compared with close surveillance alone (very low certainty).
1 finding from 1 review
Birthweight < 2500 (g) · pregnant women with a history of one or more UTI before or during pregnancy
It is very uncertain whether nitrofurantoin and close surveillance changes birthweight < 2500 (g) compared with close surveillance alone (very low certainty).
1 finding from 1 review
Birthweight (g) · pregnant women with a history of one or more UTI before or during pregnancy
1 finding from 1 review
Apgar score less than 7 at 5 minutes · pregnant women with a history of one or more UTI before or during pregnancy
It is very uncertain whether nitrofurantoin and close surveillance changes five‐minute Apgar score < seven compared with close surveillance alone (very low certainty).
1 finding from 1 review
Miscarriage · pregnant women with a history of one or more UTI before or during pregnancy
It is very uncertain whether nitrofurantoin and close surveillance changes miscarriages compared with close surveillance alone (very low certainty).
1 finding from 1 review
Endometrial Polyps · endometrial protection in women with breast cancer on adjuvant tamoxifen
The LNG‐IUS with endometrial surveillance probably leads to lower endometrial polyps compared with endometrial surveillance alone (moderate certainty).
1 finding from 1 review
Endometrial Hyperplasia · endometrial protection in women with breast cancer on adjuvant tamoxifen
The LNG‐IUS with endometrial surveillance probably leads to lower endometrial hyperplasia compared with endometrial surveillance alone (moderate certainty).
1 finding from 1 review
Endometrial cancer · endometrial protection in women with breast cancer on adjuvant tamoxifen
1 finding from 1 review
Fibroids · endometrial protection in women with breast cancer on adjuvant tamoxifen
The LNG‐IUS with endometrial surveillance showed no clear difference in fibroids compared with endometrial surveillance alone (moderate certainty).
1 finding from 1 review
Abnormal Vaginal Bleeding or Spotting · endometrial protection in women with breast cancer on adjuvant tamoxifen
The LNG‐IUS with endometrial surveillance probably leads to higher abnormal vaginal bleeding or spotting compared with endometrial surveillance alone (moderate certainty).
1 finding from 1 review
Breast cancer recurrence · endometrial protection in women with breast cancer on adjuvant tamoxifen
The LNG‐IUS with endometrial surveillance showed no clear difference in breast cancer recurrence compared with endometrial surveillance alone (moderate certainty).
1 finding from 1 review
Breast Cancer‐related Death · endometrial protection in women with breast cancer on adjuvant tamoxifen
The LNG‐IUS with endometrial surveillance showed no clear difference in breast cancer‐related death compared with endometrial surveillance alone (moderate certainty).
1 finding from 1 review
Access thrombosis/vascular complication · people receiving haemodialysis to treat kidney failure and using a functioning AV access for haemodialysis.
Scheduled surveillance showed no clear difference in risk of access thrombosis compared with clinical monitoring alone (moderate certainty).
1 finding from 1 review
Rate of angiograms · people receiving haemodialysis to treat kidney failure and using a functioning AV access for haemodialysis.
Scheduled surveillance may leads to higher rate of angiograms compared with clinical monitoring alone (low certainty).
1 finding from 1 review